Hostname: page-component-848d4c4894-sjtt6 Total loading time: 0 Render date: 2024-06-19T18:32:05.420Z Has data issue: false hasContentIssue false

466 Development of a novel tocotrienol analogue, tocoflexol, as a radiomitigator

Published online by Cambridge University Press:  24 April 2023

Shivangi Shrimali
Affiliation:
Department of Pharmaceutical Sciences, University of Arkansas for Medical Sciences
Awantika Singh
Affiliation:
Department of Pharmaceutical Sciences, University of Arkansas for Medical Sciences
Rajeshkumar Manian
Affiliation:
Tocol Pharmaceuticals LLC, Little Rock AR 72205
Shraddha Thakkar
Affiliation:
Department of Pharmaceutical Sciences, University of Arkansas for Medical Sciences
Darin E. Jones
Affiliation:
Department of Pharmaceutical Sciences, University of Arkansas for Medical Sciences
Nukhet Aykin-Burns
Affiliation:
Department of Pharmaceutical Sciences, University of Arkansas for Medical Sciences
Philip Breen
Affiliation:
Department of Pharmaceutical Sciences, University of Arkansas for Medical Sciences
Cesar M. Compadre
Affiliation:
Department of Pharmaceutical Sciences, University of Arkansas for Medical Sciences
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

OBJECTIVES/GOALS: We have designed an analogue of the Vitamin E tocotrienols called tocoflexol, which improves their pharmacokinetic limitations to make it an effective radiation medical countermeasure. Our goal is to demonstrate that tocoflexol is an effective radiomitigator in vivo when administered after exposure to lethal doses of total body irradiation. METHODS/STUDY POPULATION: Tocoflexol was designed using computational techniques to improve binding to ATTP, the key transporter that reduces the rate of elimination of tocols. In vitro studies compared the antioxidant and cell uptake properties to conventional tocotrienols. Next, we used a mouse model of lethal total body irradiation to evaluate its radioprotection efficacy (treating before radiation). To determine the optimal administration route for radiomitigation (treating after radiation), we will test oral and subcutaneous dosing. Mouse survival will be monitored for 30 days after irradiation. Sample tissues will be taken to evaluate the ability of tocoflexol to protect key organs from acute radiation syndrome. The bioavailability of tocoflexol will be evaluated in a rodent model. RESULTS/ANTICIPATED RESULTS: Known Results: Results show that tocoflexol has potent antioxidant properties and high cell uptake. When tocoflexol was administered 24 hours before exposure to lethal doses of radiation, tocoflexol-treated mice showed 100% survival. Anticipated Results: Because of its improved bioavailability and pharmacokinetic properties, we expect that tocoflexol will show radiomitigation efficacy when administered 24 hours after radiation, improving survival and protecting key organ systems from acute radiation syndrome. DISCUSSION/SIGNIFICANCE: There is an unmet need for safe and effective radiomitigators that can offer multi-organ protection and be rapidly administered in the event of nuclear emergencies. Demonstration of radiomitigation efficacy will position tocoflexol as a prime candidate to be developed into a nuclear medical countermeasure and stockpiled for emergencies.

Type
Other
Creative Commons
Creative Common License - CCCreative Common License - BYCreative Common License - NCCreative Common License - ND
This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work.
Copyright
© The Author(s), 2023. The Association for Clinical and Translational Science